Guselkumab

Drug Profile

Guselkumab

Alternative Names: CNTO-1959

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator MorphoSys
  • Developer Janssen Biotech; MorphoSys
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interleukin-23 subunit p19 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Plaque psoriasis
  • Phase III Erythrodermic psoriasis; Palmoplantar pustulosis
  • Phase II Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 03 Mar 2017 Efficacy and adverse events data from the phase III VOYAGE 2 and NAVIGATE trials in Plaque psoriasis released by Janssen
  • 03 Mar 2017 Janssen Research & Development initiates a phase III trial for Plaque psoriasis in USA, Canada (SC) (NCT02905331)
  • 01 Dec 2016 Janssen-Cilag initiates the phase IIIb POLARIS trial for Plaque psoriasis in Germany (SC) (NCT02951533)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top